Rachel Grisham MD
Gynecologic Cancer, Hematologic Oncology
Associate Attending, Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College; Section Head of Ovarian Cancer; Director Gynecologic Medical Oncology MSKCC Westchester
500 Westchester AvenueWest Harrison, NY 10604
Overview of Dr. Grisham
Dr. Rachel Grisham is an oncologist in West Harrison, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Duke University School of Medicine and has been in practice 11 years. Dr. Grisham accepts several types of health insurance, listed below. She is one of 524 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2006 - 2009
Duke University School of MedicineClass of 2006
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2027
CT State Medical License 2023 - 2026
NY State Medical License 2009 - 2026
NC State Medical License 2020 - 2022
MA State Medical License 2008 - 2009
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
Clinical Trials
- Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Start of enrollment: 2013 Nov 05
- A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Start of enrollment: 2019 May 02
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Start of enrollment: 2020 May 07
Publications & Presentations
PubMed
- Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours.Rachel N Grisham, Elizabeth Hopp, Kathryn Pennington, Robert Holloway, Robert M Wenham
Clinical and Translational Medicine. 2026-01-01 - Mitogen-Activated Protein Kinase Driven Rare Gynecologic Cancers and Evolving Therapeutic Targets.Rachel N Grisham, Aaron Praiss, Chrisann Kyi, Kay J Park
Hematology/oncology Clinics of North America. 2025-12-01 - A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer.Sara Moufarrij, Claire F Friedman, Samuel Freeman, Hunter Green, Nadeem R Abu-Rustum
Gynecologic Oncology. 2025-12-01
Press Mentions
Teen’s ‘Stomach Ache’ Was Stage 3 Ovarian Cancer. Read Her JourneyOctober 21st, 2025- Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical OncologyJuly 11th, 2025
- FDA Approves First-Ever Drug Combo for Low-Grade Serous Ovarian CancerMay 9th, 2025
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
Empire BCBS HMO
Empire BCBS PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPOMultiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
